In one paragraphArticle in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
4 authors.
Mariano A AufieroLouis V. Gerstner Jr. Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-2462-438X Li-Yin HungDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
De'Broski R HerbertDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Tobias M HohlLouis V. Gerstner Jr. Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-9097-5412 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MINITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUSR01AI093808 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HOHL, TOBIAS M · 2011 to 2020
$4.9MINITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUSR37AI093808 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI TOBIAS M HOHL · 2021 to 2026
$4.2MAntifungal Immunity and the Mechanism of Fungal Programmed Cell DeathR01AI139632 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI CRAMER, ROBERT ANDREW, HOHL, TOBIAS M · 2019 to 2023
$3.3MPerforin 2 controls unconventional cytokine release from mucosal APCU01AI163062 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HERBERT, DE'BROSKI R · 2021 to 2025
$2.4MDeciphering the Role of Lysosomal Biogenesis in Anti-Aspergillus Immune ResponsesF31AI161996 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI AUFIERO, MARIANO ALEJANDRO · 2021 to 2023
$140kNCI NIH HHS P30 CA008748NIAID NIH HHS F31 AI161996NIAID NIH HHS R01 AI093808NIAID NIH HHS R01 AI139632NIAID NIH HHS R37 AI093808NIAID NIH HHS U01 AI163062
6 · The paper itselfAbstract
Myeloid phagocytes are essential for antifungal immunity against pulmonary IMPORTANCE: Humans encounter fungal pathogens daily and rely on innate immune cells to clear
Indexed as
AspergillosisAspergillus fumigatusCandida albicansCandidiasisPore Forming Cytotoxic ProteinsAnimalsDisease Models, AnimalFemaleLungMiceMice, Inbred C57BLMice, KnockoutNeutrophilsperforin 2Pore Forming Cytotoxic ProteinsAspergillus fumigatusCandida albicansfungiinnate immunityMpeg1neutrophilPerforin
Identifiers
PMID39704516
PMCPMC11774031
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390